-
1.
公开(公告)号:US20150065699A1
公开(公告)日:2015-03-05
申请号:US14389357
申请日:2013-04-01
发明人: Guobin Ren , Changliang Dai , Jinyao Chen , Feng Chen , Minghui Qi , Wenming Zhu , Minghuang Hong , Hua Bai
IPC分类号: C07J17/00
CPC分类号: C07J17/00 , C07B2200/13 , C07J17/005
摘要: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.
摘要翻译: 提供几种类型的人参皂苷多晶型物质及其制备方法。 特别是新的晶型A,晶型B,晶型C,晶型F,晶型F,晶型I,晶型K,晶型L,晶型M,晶型N,晶型O 。
-
公开(公告)号:US09643992B2
公开(公告)日:2017-05-09
申请号:US14389345
申请日:2013-04-01
发明人: Guobin Ren , Changliang Dai , Jinyao Chen , Feng Chen , Minghui Qi , Wenming Zhu , Minghuang Hong , Hua Bai
IPC分类号: C07J17/00
CPC分类号: C07J17/005 , C07B2200/13
摘要: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.
-
公开(公告)号:US10316052B2
公开(公告)日:2019-06-11
申请号:US15324555
申请日:2015-07-07
发明人: Huijun Ren , Daochao Li , Xuexiao Ying , Feng Chen , Linghui Zheng , Lingping Wang , Hua Bai
摘要: A fidaxomicin purification method, comprising: fermenting Actinoplanes sp. HS-16-20 to generate fermented liquid; conducting solid/liquid separation on the fermented liquid, soaking mycelium in an organic solvent, and filtering to obtain a solution containing fidaxomicin; treating the solution with nanofiltration concentrate, and separating to obtain fidaxomicin crude product; conducting preparative column chromatography on the fidaxomicin crude product, eluting with an acid aqueous solution containing an organic solvent, and separating to obtain the refined fidaxomicin product.
-
4.
公开(公告)号:US20150057440A1
公开(公告)日:2015-02-26
申请号:US14389345
申请日:2013-04-01
发明人: Guobin Ren , Changliang Dai , Jinyao Chen , Feng Chen , Minghui Qi , Wenming Zhu , Minghuang Hong , Hua Bai
IPC分类号: C07J17/00
CPC分类号: C07J17/005 , C07B2200/13
摘要: Provided are ginsenoside C-K polymorphic forms and a method for preparing same. The ginsenoside C-K polymorphic forms are crystal form D and crystal form H.
摘要翻译: 提供人参皂苷C-K多晶型物及其制备方法。 人参皂甙C-K多晶型是晶型D和晶型H.
-
公开(公告)号:US20150299241A1
公开(公告)日:2015-10-22
申请号:US14646202
申请日:2013-10-25
发明人: Hua Chen , Zhiqiang Li , Linghui Zheng , Shuyi Lu , Wei Yan , Feng Chen , Lingping Wang , Hua Bai
IPC分类号: C07H1/06 , C07H15/252
CPC分类号: C07H1/06 , C07H15/252
摘要: The present invention relates to a method for preparing highly pure doxorubicin. The method comprises the following steps: (1) chromatographing a prepurified doxorubicin solution by using macroporous resin, pre-washing the chromatographed system by using an acidic low concentration aqueous organic solvent, and performing elution by using an acidic high concentration aqueous organic solvent; (2) performing chromatographic separation on eluted components by using a preparative column, so that a highly pure doxorubicin component can be obtained, and the doxorubicin can, if needed, be separated from the aqueous solution by using conventional concentration and crystallization methods in the prior art. The present invention has the advantages such as simplicity, high yield, low cost, and less environmental pollution. The content of the prepared doxorubicin is greater than 99.5%, the content of each impurity is controlled to be lower than 0.10%, and the USP and EP standards are met.
摘要翻译: 本发明涉及制备高纯度多柔比星的方法。 该方法包括以下步骤:(1)通过使用大孔树脂对预纯化的多柔比星溶液进行色谱分离,使用酸性低浓度有机有机溶剂对色谱系统进行预洗涤,并使用酸性高浓度有机有机溶剂进行洗脱; (2)使用制备柱对洗脱成分进行色谱分离,从而可以获得高纯度的多柔比星组分,如果需要,可以通过使用常规的浓缩和结晶方法将多柔比星与水溶液分离 艺术。 本发明具有简单,成品率高,成本低,环境污染少等优点。 制备的多柔比星的含量大于99.5%,每种杂质的含量控制在0.10%以下,符合USP和EP标准。
-
公开(公告)号:US09670245B2
公开(公告)日:2017-06-06
申请号:US14389357
申请日:2013-04-01
发明人: Guobin Ren , Changliang Dai , Jinyao Chen , Feng Chen , Minghui Qi , Wenming Zhu , Minghuang Hong , Hua Bai
IPC分类号: C07J17/00
CPC分类号: C07J17/00 , C07B2200/13 , C07J17/005
摘要: Provided are several types of ginsenoside polymorphic substances and a method for preparing same. In particular, new crystal form A, crystal form B, crystal form C, crystal form E, crystal form F, crystal form I, crystal form K, crystal form L, crystal form M, crystal form N, and crystal form O are involved.
-
-
-
-
-